Potential usefulness of urinary L-FABP stems from clinical evidence showing its negative correlation with eGFR and renal function decline (114); such evidence was confirmed also in prospective cohorts of CKD older patients, where high urinary L-FABP has been associated with eGFR decline in patients without albuminuria (114), as well as with progression to ESKD and incidence of CVD, irrespective of diabetes (113). This evidence concerns the gene FABP1 and chronic kidney disease.